← Back to Clinical Trials
Recruiting NCT04826744

NCT04826744 Frequency of Palpebral Involvement in Adult With Atopic Dermatitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04826744
Status Recruiting
Phase
Sponsor University Hospital, Lille
Condition Atopic Dermatitis
Study Type OBSERVATIONAL
Enrollment 550 participants
Start Date 2021-09-01
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Standard dermatology consultation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 550 participants in total. It began in 2021-09-01 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Atopic dermatitis is a common inflammatory skin disease, resulting from genetical, immunological and environmental factors. Head and neck are among the most frequent involved areas, almost 50% in adult patients according to most publications. Palpebral involvement is also common and a source of major quality of life impairment for patients. However, the real frequency of this palpebral involvement is unknown, only estimated about 20% in few studies. The treatment of this location remains difficult, regarding to the thickness of palpebral skin and proximity of the eye. To our knowledge, no prospective studies about allergological skin tests (such as patch-tests) in atopic patients with palpebral involvement had been conducted. Finally, atopic dermatitis is frequently associated with ophthalmological diseases such as conjunctivitis, keratoconus or cataract, which belong to the minor criteria of Hanifin and Rakja classification. A better knowledge of the atopic dermatitis palpebral involvement and the associated factors seems to be needed to improve the treatment and the quality of life of patients

Eligibility Criteria

Inclusion Criteria: * Atopic Dermatitis according to the revised Hanifin and Rakja criteria (UK Working Party) * Oral consent * Valid social insurance Exclusion Criteria: * Personal history of uncontrolled asthma * No social insurance * Protective measures * Age under 18 * Pregnancy or breast-feeding

Contact & Investigator

Central Contact

Delphine Staumont-Salle, MD,PhD

✉ delphine.salle@chru-lille.fr

📞 0320445962

Principal Investigator

Delphine Staumont-Salle, MD,PhD

PRINCIPAL INVESTIGATOR

University Hospital, Lille

Frequently Asked Questions

Who can join the NCT04826744 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04826744 currently recruiting?

Yes, NCT04826744 is actively recruiting participants. Contact the research team at delphine.salle@chru-lille.fr for enrollment information.

Where is the NCT04826744 trial being conducted?

This trial is being conducted at Lille, France, Rouen, France.

Who is sponsoring the NCT04826744 clinical trial?

NCT04826744 is sponsored by University Hospital, Lille. The principal investigator is Delphine Staumont-Salle, MD,PhD at University Hospital, Lille. The trial plans to enroll 550 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology